In short
This article provides an overview of clinical trials investigating the use of the Influenza Virus A/Thailand/8/2022 (H3N2) strain in seasonal influenza vaccines. These studies aim to evaluate the safety, efficacy, and immunogenicity of new vaccine formulations containing this strain compared to existing licensed vaccines. The trials focus on adult populations, particularly those aged 65 and older, who are at higher risk for flu complications.
What is INFLUENZA VIRUS A/THAILAND/8/2022 (H3N2) IVR-237-LIKE STRAIN (A/THAILAND/8/2022)?
INFLUENZA VIRUS A/THAILAND/8/2022 (H3N2) IVR-237-LIKE STRAIN (A/THAILAND/8/2022) is a component of influenza vaccines designed to protect against a specific strain of the influenza virus. This strain is part of the H3N2 subtype of influenza A viruses, which are known to cause seasonal flu epidemics in humans.
The name of this strain provides important information:
- "A" indicates it's an influenza A virus
- "Thailand" refers to where the virus was first isolated
- "8/2022" likely indicates it was the 8th isolate in 2022
- "H3N2" describes the specific proteins on the virus surface
- "IVR-237-like" suggests it's similar to a laboratory reference strain
How does it work?
This strain is included in influenza vaccines to stimulate the immune system to produce antibodies against the H3N2 virus. When your body encounters the actual virus later, it can recognize and fight it off more effectively, reducing your chances of getting sick or experiencing severe symptoms.
Clinical Trials and Research
Clinical trials are being conducted to evaluate the effectiveness of vaccines containing this strain. One such study is a Phase 3/3b trial comparing an MF59-adjuvanted subunit inactivated influenza vaccine to a non-adjuvanted influenza vaccine in adults aged 65 and older.
The main objectives of this study include:
- Demonstrating the efficacy of the adjuvanted vaccine in preventing RT-PCR-confirmed influenza A and/or B disease
- Evaluating the safety of the adjuvanted vaccine
- Assessing the immunogenicity (ability to provoke an immune response) of the adjuvanted vaccine compared to the non-adjuvanted vaccine
Another ongoing study is investigating an mRNA-based influenza vaccine (mRNA-1010) compared to a licensed inactivated seasonal influenza vaccine in adults aged 50 and older. This study aims to evaluate the safety, efficacy, and immunogenicity of the mRNA vaccine.
How is it administered?
The vaccine containing this influenza strain is typically administered as an intramuscular injection. The usual dose is 0.5 ml, given once per flu season. It's often delivered using a pre-filled syringe for convenience and accuracy.
Who can receive this vaccine?
The specific vaccines containing this strain are being studied in adults aged 65 and older, as well as those 50 and older, depending on the particular clinical trial. However, the exact approved age range may vary based on the final study results and regulatory approvals.
Some people who should not receive the vaccine include:
- Those with severe allergies to vaccine components
- Individuals with a history of severe reactions to previous influenza vaccinations
- People with certain medical conditions (always consult your healthcare provider)
Potential Side Effects
While specific side effects for this particular strain are not detailed in the provided information, common side effects of influenza vaccines may include:
- Pain, redness, or swelling at the injection site
- Low-grade fever
- Mild body aches
Serious side effects are rare but can occur. The clinical trials mentioned are closely monitoring for any adverse events.
Effectiveness
The effectiveness of this specific strain in preventing influenza is being studied in the ongoing clinical trials. The researchers are looking at various measures of effectiveness, including:
- Prevention of laboratory-confirmed influenza
- Reduction in influenza-like illness (ILI) symptoms
- Immune response as measured by antibody levels
Results from these studies will provide more information about how well this strain protects against the current circulating H3N2 viruses.
Conclusion
The INFLUENZA VIRUS A/THAILAND/8/2022 (H3N2) IVR-237-LIKE STRAIN (A/THAILAND/8/2022) is an important component of current influenza vaccines. Ongoing research aims to improve vaccine effectiveness and explore new vaccine technologies. As always, consult with your healthcare provider to determine if vaccination is appropriate for you and to address any concerns you may have.